Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT Glioblastoma Trial (GlobeNewswire) - Jun 16, 2021 - "Plus Therapeutics, Inc...announced that the Data and Safety Monitoring Board recommended the Company proceed to the eighth cohort of the Phase 1 dose escalation ReSPECT™ trial, which is evaluating the Company's lead investigational drug, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM)....The eighth cohort of the ReSPECT™ trial will implement a 40% increase in total radioactivity. The planned infused dose will be 31.2 millicuries in a volume of 12.3 milliliters (increased from 22.3 millicuries and 8.8 milliliters, respectively, used in cohort seven). The planned maximum flow rate will not change."
DSMB • Trial status • Glioblastoma • Oncology
|